2024

Catalogue

promise

ADVANCED PROTEOMICS

SIL-mAbs

FOR TARGETED LC-MS QUANTIFICATION

The gold standard for robust and reliable quantitative LC-MS workflow

www.promise-proteomics.com | contact@promise-proteomics.com

SIL-MONOCLONAL ANTIBODIES

Promise Proteomics is a pioneer and an expert
in the development of mass spectrometry-based quantification methods
and in bioproduction of Stable Isotope Labelled monocolonal Antibodies (SIL-mAbs)

Why use our SIL-mAbs ?

A stable isotope labelled (SIL) form of an analyte protein is widely regarded as the optimal internal standard[1] for absolute quantification of proteins using LC-MS.

SIL-mAbs correct bias (due to losses, incomplete digestion, adsorption, proteolysis...) occuring during the preparation and analytical workflow. With SIL-mAbs, the accuracy and reproducibility of your quantification data is improved.

This product is useful for :

- Bioanalysis pharmacokinetics studies (clinical & nonclinical),
- Research and Discovery/pre-clinical/clinical drug development

Characteristics

- **Full length recombinant monoclonal antibodies**
- **High isotopic incorporation (>98%) and purity (>95%)**
- **Labelling on Arg, Lys residues,** ^{13}C ^{15}N isotope
- **Expression systems CHO or HEK**

How to use it ?



Sample collection | Addition of SIL-mAb | Sample clean-up | mAb digestion | LC-MS analysis | Accurate quantification

Unlike the use of SIL-peptides, Promise's SIL-mAbs are processed along with the target analytes throughout the pre-analytical and LC-MS workflow thus improving robustness and quality of the quantitative data.

1. Todoroki, K. *et al.* (2020, février). Bioanalytical methods for therapeutic monoclonal antibodies and antibody–drug conjugates : A review of recent advances and future perspectives. Journal of Pharmaceutical and Biomedical Analysis, 179, 112991. https://doi.org/10.1016/j.jpba.2019.112991

OFF-THE-SHELF PRODUCTS

SIL-mAbs* are available to support your studies and clinical trials

SIL-MONOCLONAL ANTIBODIES	REFERENCE
Abatacept	ORF90261
Adalimumab	HUU05211
Alemtuzumab	ALZ10131
Avelumab	BAH92571
Bevacizumab	AVZ10161
Belatacept	Upon request
Cetuximab	ERX08221
Concizumab	COZ13241
Daratumumab	DAU05201
Dupilumab	DUU08301
Durvalumab	IMU05501
Eculizumab	SOZ11141
Emicizumab	HEH95561
Epcoritamab	EPZ10171
Etanercept	ENF90251
Golimumab	SIU05281
Guselkumab	TRU05271
Infliximab	REX08151
Ipilimumab	YEH92271
Ixekizumab	TAZ13261
Nivolumab	OPH95701
Obinutuzumab	GAH92161
Ocrelizumab	OCZ10231
Pembrolizumab	KEH95331
Pertuzumab	PEZ10191
Risankizumab	SKZ10121
Rituximab	RIX08221
Secukinumab	COH92201
Siltuximab	SYX08151
Tocilizumab	ACH92241
Trastuzumab	HEZ10231
Ustekinumab	STU05261
Vedolizumab	ENZ10211

**for Research Use Only*

Is your SIL-mAb of interest not listed?

For 10 years, Promise Proteomics offers **customized bioproduction options**. Contact us for further information.

bsi ISO 9001 Quality Management CERTIFIED

contact@promise-proteomics.com

REFERENCES

Peer reviewed publications using our SIL-mAbs

- **University Medical Center Utrecht**

Smeijsters, E. H. E. *et al*. (2023). Optimization of a quantitative Anti-Drug Antibodies against Infliximab assay with the liquid Chromatography-Tandem Mass Spectrometry : A Method Validation Study and Future Perspectives. Pharmaceutics, 15(5), 1477. https://doi.org/10.3390/pharmaceutics15051477

- **University Medical Center Utrecht**

el Amrani, M. *et al* (2019). Quantification of neutralizing anti-drug antibodies and their neutralizing capacity using competitive displacement and tandem mass spectrometry : Infliximab as proof of principle. Journal of Translational Autoimmunity, 1, 100004. https://doi.org/10.1016/j.jtauto.2019.100004

- **Hospices Civils de Lyon**

Millet, A. *et al.* (2019). Determination of Cetuximab in Plasma by Liquid Chromatography–High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal Standard. Therapeutic Drug Monitoring, 41(4), 467-475. https://doi.org/10.1097/ftd.0000000000000613

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2018). Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography–Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 40(4), 417-424. https://doi.org/10.1097/ftd.0000000000000514

- **University Hospital Grenoble-Alpes**

Jourdil, J. F. *et al.* (2016). Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry : towards a standardization of the methods ? Analytical and Bioanalytical Chemistry, 409(5), 1195-1205. https://doi.org/10.1007/s00216-016-0045-4

- **University Medical Center Utrecht**

el Amrani, M. *et al.* (2016). Quantification of active infliximab in human serum with liquid chromatography–tandem mass spectrometry using a tumor necrosis factor alpha -based pre-analytical sample purification and a stable isotopic labeled infliximab bio-similar as internal standard : A target-based, sensitive and cost-effective method. Journal of Chromatography A, 1454, 42-48. https://doi.org/10.1016/j.chroma.2016.05.070